Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study

Open access
Glue, Paul, Medlicott, Natalie J., Neehoff, Shona, Surman, Peter, Lam, Fred, Hung, Noelyn, Hung, Cheung-tak · 2020 · Therapeutic Advances in Psychopharmacology

Abstract

Background: Ketamine’s defining side effects are dissociation and increased blood pressure/heart rate. An oral formulation with delayed absorption could minimize these effects. We recently reported safety and tolerability data for an extended release ketamine tablet in healthy volunteers. Methods: To assess safety, tolerability, efficacy, and pharmacokinetics of an extended release oral ketamine tablet in patients with treatment-resistant depression/anxiety. This was a multiple dose open-label flexible dose uncontrolled study in seven patients with treatment-resistant depression/anxiety, who had all previously demonstrated mood improvement to subcutaneous ketamine. Assessments included ratings of anxiety, depression and dissociation, safety and tolerability, and blood samples for ketamine pharmacokinetics and brain-derived neurotrophic factor (BDNF) concentrations. Results: Improvements in anxiety and depression ratings occurred gradually over 96 h; all patients had >50% improvements in mood ratings. Ketamine was safe and well tolerated, with no changes in vital signs, and a single brief report of dissociation. Ketamine may induce its own metabolism, as the ratio of norketamine to ketamine increased out to 96 h. Serum BDNF concentrations did not change during the study. Conclusion: Ketamine’s safety/tolerability may be improved with an extended release oral formulation. Onset of mood improvement is slightly delayed compared with parenteral dosing. These data support the further development of extended release ketamine tablets for treatment of resistant depression and anxiety disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2045125320922474

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Effect of extended release ketamine tablets on mean (SEM) HAMA (A), FQ (B), and MADRS (C) scores. HAMA, Hamilton anxiety scale; FQ, fear questionnaire; MADRS, Montgomery-Asberg depression rating scale; SEM, standard error of the mean.
Figure 1. Effect of extended release ketamine tablets on mean (SEM) HAMA (A), FQ (B), and MADRS (C) scores. HAMA, Hamilton anxiety scale; FQ, fear questionnaire; MADRS, Montgomery-Asberg depression rating scale; SEM, standard error of the mean.CC BY-NC · PubMed Central
Figure 2. (A) Mean concentration-time profiles for ketamine and norketamine after 12 hourly dosing of extended release ketamine tablets out to 72 h. (B) Individual norketamine:ketamine ratios over time, with a fitted regression line. (C) Mean serum BDNF concentration-time profiles after 12 hourly dosing of extended release ketamine tablets out to 72 h. BDNF, brain-derived neurotrophic factor.
Figure 2. (A) Mean concentration-time profiles for ketamine and norketamine after 12 hourly dosing of extended release ketamine tablets out to 72 h. (B) Individual norketamine:ketamine ratios over time, with a fitted regression line. (C) Mean serum BDNF concentration-time profiles after 12 hourly dosing of extended release ketamine tablets out to 72 h. BDNF, brain-derived neurotrophic factor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 2

  1. Glue P, 2019, Extended release pharmaceutical formulation
  2. Lin F, 2015, Int J Clin Exper Med, 8, 4335

Cited by

See all 42

Metadata

Authors
Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T.
Affiliations
  • University of Otago (NZ)
  • Douglas Pharmaceuticals (New Zealand) (NZ)
  • Zenith Technology Ltd, Dunedin, New Zealand
Corresponding author
Glue, Paul
Venue
Therapeutic Advances in Psychopharmacology
Published
2020-01
Volume
10
Pages
2045125320922474-2045125320922474
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W3026895695
Cited by
42
References
19
Citations by year
2026: 6 · 2025: 15 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 5 · 2020: 2
FWCI
2.25
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
douglas pharmaceuticals
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
treatment-resistant depression, anxiety disorders, dissociation, brain-derived neurotrophic factor, safety and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. https://app.cochat.ai/papers/10.1177/2045125320922474
The paper
Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320922474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.